Efficacy of Albumin (drug) in liver disease with acute kidney injury (kidney disease)
- Conditions
- Health Condition 1: K746- Other and unspecified cirrhosis ofliver
- Registration Number
- CTRI/2020/06/026064
- Lead Sponsor
- Institute of Liver and Biliary Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 0
1) Patients who are above 18 years of age
2) Patients with Cirrhosis and SBP (community acquired /Health care associated/ nosocomial) with baseline Creatinine <1mg/dl, Bilirubin <4mg/dl
1) Antibiotic treatment within one week before the diagnosis of SBP (except for prophylactic treatment with norfloxacin)
2) Significant cardiac failure, pulmonary disease
3) Known Chronic Kidney Disease or findings suggestive of organic nephropathy (proteinuria, haematuria, or abnormal findings on renal USG)
4) Hepatocellular carcinoma
5) HIV infection;
6) GI bleed within 1 month before the study
Ileus
7) Grade 3 to 4 hepatic encephalopathy
8) Other types of infection
9) Shock
10) Serum Bilirubin >=4 mg/dL and Serum Creatinine >= 1 mg/dl at presentation
11) Patients requiring Albumin for any other indication.
12) Presence of any potential causes of dehydration (such as diarrhea or an intense response to diuretic treatment) within one week before the diagnosis of SBP).
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of patients having development / progression of Acute Kidney Injury in both groups.Timepoint: Day 7
- Secondary Outcome Measures
Name Time Method Change in PRA,TNF alpha & IL-6 in both groupsTimepoint: Day 7;Change in Renal resistive index in both groupsTimepoint: Day 7;Mortality in both groupsTimepoint: Day 7 and Day 28;Resolution of Spotaneous Bacterial Peroitonoitis in both groupsTimepoint: Day 2 and Day 7